SCHEMBL1655857

SCHEMBL1655857

Cc1ccccc1NC(=O)Nc1cccc(NC(N)=O)c1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDX3X O00571 3/20 0.85
POLB P06746 4/20 0.62
RAB9A P51151 5/20 0.57
NPC1 O15118 4/20 0.57
ITGB1 P05556 1/20 0.54
ITGA4 P13612 1/20 0.54
KMT2A Q03164 4/20 0.54
MEN1 O00255 3/20 0.54
MAPT P10636 2/20 0.54
HTT P42858 2/20 0.54
IMPDH2 P12268 1/20 0.53
KDM4E B2RXH2 2/20 0.51
LMNA P02545 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
PDGFRB P09619 1/20 0.50
KDR P35968 1/20 0.50
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA9 Q16790 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11918074 0.92 DDX3X (1.00) DDX3XPOLBRAB9ANPC1ITGB1
SCHEMBL1659299 0.92 DDX3X (1.00) DDX3XPOLBRAB9ANPC1ITGB1
SCHEMBL1657638 0.85 DDX3X (1.00) DDX3XPOLBRAB9ANPC1ITGB1
SCHEMBL10192076 0.84 DDX3X (0.84) DDX3XPOLBRAB9ANPC1KMT2A
SCHEMBL812756 0.82 DDX3X (0.80) DDX3XPOLBRAB9ANPC1ITGB1
SCHEMBL17189470 0.82 SIRT1 (0.66) DDX3XPOLBRAB9ANPC1KMT2A
SCHEMBL17079616 0.82 DDX3X (0.79) DDX3XRAB9ANPC1KMT2AMEN1
SCHEMBL17079631 0.82 DDX3X (0.79) DDX3XRAB9ANPC1KMT2AMEN1
SCHEMBL17079603 0.82 DDX3X (0.79) DDX3XRAB9ANPC1KMT2AMEN1
SCHEMBL81434 0.82 POLB (0.75) DDX3XPOLBRAB9ANPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120202814-A1 COMPOUNDS WITH DDX3 INHIBITORY ACTIVITY AND USES THEREOF UNIVERSITÀ DEGLI STUDI DI SIENA (IT) 2012-08-09 US disclosed
US-20120202814-A1 COMPOUNDS WITH DDX3 INHIBITORY ACTIVITY AND USES THEREOF UNIVERSITÀ DEGLI STUDI DI SIENA (IT) 2012-08-09 US disclosed
WO-2011039735-A2 COMPOUNDS WITH DDX3 INHIBITORY ACTIVITY AND USES THEREOF CONSIGLIO NAZIONALE DELLE RICERCHE (IT) 2011-04-07 WO disclosed
WO-2011039735-A2 COMPOUNDS WITH DDX3 INHIBITORY ACTIVITY AND USES THEREOF CONSIGLIO NAZIONALE DELLE RICERCHE (IT) 2011-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202814-A1 COMPOUNDS WITH DDX3 INHIBITORY ACTIVITY AND USES THEREOF DDX3X, DDX21, DDX39B DDX3X 1/4885POLB 658/4885RAB9A 2819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.